Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy.
Colorectal cancer
KRAS
Neuropathy
Oxaliplatin
Statin
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
17 Apr 2023
17 Apr 2023
Historique:
received:
15
11
2022
accepted:
01
03
2023
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
epublish
Résumé
KRAS mutations are fraught with the progression of colorectal cancer and resistance to chemotherapy. There are pathways such as extracellular regulated protein kinase 1/2 (ERK1/2) and Akt downstream and farnesylation and geranylgeranylation upstream that are activated upon mutated KRAS. Previous studies have shown that statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are effective to treat KRAS mutated colorectal cancer cells. Increased doses of oxaliplatin (L-OHP), a well-known alkylating chemotherapeutic drug, causes side effects such as peripheral neuropathy due to ERK1/2 activation in spinal cords. Hence, we examined the combinatorial therapeutic efficacy of statins and L-OHP to reduce colorectal cancer cell growth and abrogate neuropathy in mice. Cell survival and confirmed apoptosis was assessed using WST-8 assay and Annexin V detection kit. Detection of phosphorylated and total proteins was analyzed the western blotting. Combined effect of simvastatin and L-OHP was examined the allograft mouse model and L-OHP-induced neuropathy was assessed using cold plate and von Frey filament test. In this study, we examined the effect of combining statins with L-OHP on induction of cell death in colorectal cancer cell lines and improvement of L-OHP-induced neuropathy in vivo. We demonstrated that combined administration with statins and L-OHP significantly induced apoptosis and elevated the sensitivity of KRAS-mutated colorectal cancer cells to L-OHP. In addition, simvastatin suppressed KRAS prenylation, thereby enhancing antitumor effect of L-OHP through downregulation of survivin, XIAP, Bcl-xL, and Bcl-2, and upregulation of p53 and PUMA via inhibition of nuclear factor of κB (NF-κB) and Akt activation, and induction of c-Jun N-terminal kinase (JNK) activation in KRAS-mutated colorectal cancer cells. Moreover, simvastatin enhanced the antitumor effects of L-OHP and suppressed L-OHP-induced neuropathy via ERK1/2 activation in vivo. Therefore, statins may be therapeutically useful as adjuvants to L-OHP in KRAS-mutated colorectal cancer and may also be useful in the treatment of L-OHP-induced neuropathy.
Sections du résumé
BACKGROUND
BACKGROUND
KRAS mutations are fraught with the progression of colorectal cancer and resistance to chemotherapy. There are pathways such as extracellular regulated protein kinase 1/2 (ERK1/2) and Akt downstream and farnesylation and geranylgeranylation upstream that are activated upon mutated KRAS. Previous studies have shown that statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are effective to treat KRAS mutated colorectal cancer cells. Increased doses of oxaliplatin (L-OHP), a well-known alkylating chemotherapeutic drug, causes side effects such as peripheral neuropathy due to ERK1/2 activation in spinal cords. Hence, we examined the combinatorial therapeutic efficacy of statins and L-OHP to reduce colorectal cancer cell growth and abrogate neuropathy in mice.
METHODS
METHODS
Cell survival and confirmed apoptosis was assessed using WST-8 assay and Annexin V detection kit. Detection of phosphorylated and total proteins was analyzed the western blotting. Combined effect of simvastatin and L-OHP was examined the allograft mouse model and L-OHP-induced neuropathy was assessed using cold plate and von Frey filament test.
RESULTS
RESULTS
In this study, we examined the effect of combining statins with L-OHP on induction of cell death in colorectal cancer cell lines and improvement of L-OHP-induced neuropathy in vivo. We demonstrated that combined administration with statins and L-OHP significantly induced apoptosis and elevated the sensitivity of KRAS-mutated colorectal cancer cells to L-OHP. In addition, simvastatin suppressed KRAS prenylation, thereby enhancing antitumor effect of L-OHP through downregulation of survivin, XIAP, Bcl-xL, and Bcl-2, and upregulation of p53 and PUMA via inhibition of nuclear factor of κB (NF-κB) and Akt activation, and induction of c-Jun N-terminal kinase (JNK) activation in KRAS-mutated colorectal cancer cells. Moreover, simvastatin enhanced the antitumor effects of L-OHP and suppressed L-OHP-induced neuropathy via ERK1/2 activation in vivo.
CONCLUSION
CONCLUSIONS
Therefore, statins may be therapeutically useful as adjuvants to L-OHP in KRAS-mutated colorectal cancer and may also be useful in the treatment of L-OHP-induced neuropathy.
Identifiants
pubmed: 37069612
doi: 10.1186/s12935-023-02884-z
pii: 10.1186/s12935-023-02884-z
pmc: PMC10108455
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K07168
Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 1999 Aug;5(8):2223-9
pubmed: 10473109
Neurol Res. 2019 Dec;41(12):1059-1068
pubmed: 31584354
Pharmaceuticals (Basel). 2020 Dec 31;14(1):
pubmed: 33396362
Haematologica. 2007 May;92(5):682-5
pubmed: 17488694
Tumour Biol. 2018 Oct;40(10):1010428318808670
pubmed: 30360692
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33
pubmed: 12422305
Oncol Lett. 2021 Jun;21(6):481
pubmed: 33968197
Mol Cancer. 2021 Oct 4;20(1):128
pubmed: 34607583
Clin Cancer Res. 2004 Dec 15;10(24):8648-55
pubmed: 15623649
Ann Transl Med. 2018 Dec;6(Suppl 2):S96
pubmed: 30740417
Am J Cancer Res. 2018 Jul 01;8(7):1239-1248
pubmed: 30094097
EMBO Mol Med. 2011 May;3(5):266-78
pubmed: 21438154
Cancers (Basel). 2021 May 03;13(9):
pubmed: 34063682
Clin Exp Pharmacol Physiol. 2017 Feb;44(2):222-234
pubmed: 27805296
J Natl Cancer Inst. 2011 Oct 19;103(20):1540-51
pubmed: 21849660
PLoS One. 2014 Nov 06;9(11):e112201
pubmed: 25375154
Int J Cancer. 2008 Aug 15;123(4):951-7
pubmed: 18521906
Muscle Nerve. 2005 Jul;32(1):51-60
pubmed: 15880395
Biomed Pharmacother. 2016 Mar;78:23-29
pubmed: 26898421
Front Pain Res (Lausanne). 2021 Dec 08;2:804260
pubmed: 35295491
PLoS One. 2019 Nov 25;14(11):e0225586
pubmed: 31765435
Tumour Biol. 2017 Oct;39(10):1010428317734947
pubmed: 28990465
Br J Pharmacol. 2022 Jun;179(12):2844-2867
pubmed: 33634485
Pain. 2000 May;86(1-2):95-101
pubmed: 10779666
Hematol Oncol. 2009 Mar;27(1):17-22
pubmed: 18668701
Front Mol Biosci. 2021 May 07;8:643824
pubmed: 34026827
Dis Colon Rectum. 2013 Nov;56(11):1217-27
pubmed: 24104995
Gastroenterology. 2017 Aug;153(2):470-479.e4
pubmed: 28512021
J Natl Cancer Inst. 2011 Apr 20;103(8):674-88
pubmed: 21398618
Eur J Pharmacol. 2021 May 5;898:173957
pubmed: 33662352
Am J Clin Oncol. 2021 Feb 1;44(2):68-73
pubmed: 33298767
J Exp Clin Cancer Res. 2011 Aug 10;30:74
pubmed: 21831290
Cytokine. 2021 Aug;144:155591
pubmed: 34052656
J Toxicol Pathol. 2016 Oct;29(4):253-259
pubmed: 27821910
Anticancer Agents Med Chem. 2018;18(3):428-437
pubmed: 29076434
Ann Pharmacother. 2005 Jan;39(1):128-35
pubmed: 15590869
Int J Cancer. 2015 Jul 1;137(1):243-50
pubmed: 25430564
Biochemistry. 2003 Apr 22;42(15):4384-91
pubmed: 12693933
Gynecol Oncol. 2010 Dec;119(3):549-56
pubmed: 20837358
J Clin Oncol. 2009 Feb 10;27(5):663-71
pubmed: 19114683
PLoS One. 2017 Apr 26;12(4):e0174848
pubmed: 28445513
JAMA Oncol. 2016 May 01;2(5):643-653
pubmed: 26768652
Evid Based Complement Alternat Med. 2021 Sep 13;2021:2280440
pubmed: 34557254
Eur J Pharmacol. 2000 Oct 6;406(1):25-32
pubmed: 11011028
Surgery. 2022 Apr;171(4):890-896
pubmed: 34507829